SEC Company Response from Voyager Therapeutics, (VYGR) — Nov 26, 2025
Voyager Therapeutics, Inc.
Date: Nov. 26, 2025 · CIK: 0001640266 · Accession: 0001104659-25-116421
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291418
Letter
VOYAGER THERAPEUTICS, INC.
75 Hayden Avenue
Lexington, MA 02421
November 26, 2025
VIA EDGAR SUBMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Voyager Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-291418 Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Voyager Therapeutics, Inc. (the " Registrant ") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-291418), so that it may become effective at 4:30 p.m., Eastern time, on December 1, 2025, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
Very truly yours,
VOYAGER THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm VOYAGER THERAPEUTICS, INC. 75 Hayden Avenue Lexington, MA 02421 November 26, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Voyager Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-291418 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Voyager Therapeutics, Inc. (the " Registrant ") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-291418), so that it may become effective at 4:30 p.m., Eastern time, on December 1, 2025, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff. Very truly yours, VOYAGER THERAPEUTICS, INC. By: /s/ Nathan Jorgensen Name: Nathan Jorgensen Title: Chief Financial Officer cc: Scott Townsend Senior Vice President of Legal and Chief Corporate Counsel Voyager Therapeutics, Inc. Robin Swartz Chief Business Officer and Chief Operating Officer Voyager Therapeutics, Inc. Brian A. Johnson C.S. Avery Reaves Wilmer Cutler Pickering Hale and Dorr LLP